title: Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
abstract: A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea. Psychometric ratings with positive and negative syndrome scale (PANSS) and brief psychiatric rating scale (BPRS) were measured at baseline, week 4 and week 8; as were weight and body mass index (BMI). A combination of nizatidine for 8 weeks resulted in significant reversal of weight gain without worsening the psychopathology (weight: 3.5% and BMI: 3.7%). In line with studies of Western populations, an add-on therapy of nizatidine could be an effective option for the control of weight gain in olanzapine-treated patients in Korea. Our findings call for further evaluation of the effect of this drug on OAWG, with randomized placebo-controlled studies, in Asian populations.
authors.affiliation: Department of Psychiatry, Kangnam St Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-Dong, Seocho-Gu, Seoul 137-701, Korea.
authors.forename: Chi-Un
authors.initials: CU
authors.lastname: Pae
authors.forename: Jung-Jin
authors.initials: JJ
authors.lastname: Kim
authors.forename: Kyung-Uk
authors.initials: KU
authors.lastname: Lee
authors.forename: Chang-Uk
authors.initials: CU
authors.lastname: Lee
authors.forename: Won-Myong
authors.initials: WM
authors.lastname: Bahk
authors.forename: Soo-Jung
authors.initials: SJ
authors.lastname: Lee
authors.forename: Chul
authors.initials: C
authors.lastname: Lee
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Paik
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016567:Nizatidine / Q000008:administration & dosage* / Q000627:therapeutic use; D009765:Obesity / Q000209:etiology / Q000517:prevention & control; D000077152:Olanzapine; D010865:Pilot Projects; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D006635:Histamine H2 Antagonists; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine; D016567:Nizatidine